Amarin Seeks Injunction Blocking FDA's Off-Label Muzzle
Amarin Pharma Inc. and doctors claiming the U.S. Food and Drug Administration has violated their First Amendment rights by restricting "truthful and non-misleading" statements about off-label uses for cardiovascular drug Vascepa...To view the full article, register now.
Already a subscriber? Click here to view full article